Evaluation of Mycograb®, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies

This publication has 67 references indexed in Scilit:

• Genetically recombinant antibodies: new therapeutics against candidiasis
  Expert Opinion on Biological Therapy, 2004
• Cryptococcus neoformans var. neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia
  Clinical Microbiology & Infection, 2003
• The role of antibodies against hsp90 in the treatment of fungal infections
  Drug News & Perspectives, 2003
• Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate
  Antimicrobial Agents and Chemotherapy, 2002
• A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology
  Diagnostic Microbiology and Infectious Disease, 2000
• Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans
  Antimicrobial Agents and Chemotherapy, 2000
• Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection
  Antimicrobial Agents and Chemotherapy, 2000
• The Hidden Danger of Primary Fluconazole Prophylaxis for Patients with AIDS
  Clinical Infectious Diseases, 1998
• Possible Development of Resistance to Fluconazole During Suppressive Therapy for AIDS-Associated Cryptococcal Meningitis
  Clinical Infectious Diseases, 1996
• A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis
  New England Journal of Medicine, 1979